, as well as data from studies carried out once the vaccine was deployed during the 2022 mpox outbreak. More than 1.2 million people in the United States received at least one dose of the vaccine at that time, and studies showed it provided a high level of protection against mpox.
Yet the W.H.O. did not open formal consideration of that research until last week.
Deusdedit Mubangizi, the W.H.O.’s director of health product policy and standards, said that the organization’s group of experts would meet the week of Sept. 16 to consider the submitted data, and could issue a license as early as that week if they were satisfied.